Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H16F4N4O2S |
Molecular Weight | 476.447 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=C(F)C=C(C=C1)N2C(=S)N(C(=O)C23CCC3)C4=CC(=C(C=C4)C#N)C(F)(F)F
InChI
InChIKey=JPQFGMYHKSKKGW-UHFFFAOYSA-N
InChI=1S/C22H16F4N4O2S/c1-28-18(31)15-6-5-14(10-17(15)23)30-20(33)29(19(32)21(30)7-2-8-21)13-4-3-12(11-27)16(9-13)22(24,25)26/h3-6,9-10H,2,7-8H2,1H3,(H,28,31)
Molecular Formula | C22H16F4N4O2S |
Molecular Weight | 476.447 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19359544Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21397833
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19359544
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21397833
RD 162 was optimized from a screen for non-steroidal antiandrogens that retain activity in the setting of increased androgen receptor expression. RD 162 binds
to the androgen receptor with greater relative affinity than the clinically used antiandrogen
bicalutamide, reduce the efficiency of its nuclear translocation and impair both DNA binding to
androgen response elements and recruitment of coactivators. RD 162 is orally
available and induce tumor regression in mouse models of castration-resistant human prostate cancer.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19359544 |
50.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. | 2009 May 8 |
|
Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. | 2011 Jan 1 |
|
[Strategies in castration-resistant prostate cancer]. | 2011 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19359544
Mice: mice were treated for 5 days with 10 mg/kg RD 162 daily by oral gavage
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19359544
In the human prostate cancer cell line VCaP which has endogenous AR gene amplification, RD 162 (1 and 10 uM) suppressed growth and induced apoptosis
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:43:29 UTC 2023
by
admin
on
Sat Dec 16 18:43:29 UTC 2023
|
Record UNII |
5ZE6THH5VF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11957756
Created by
admin on Sat Dec 16 18:43:29 UTC 2023 , Edited by admin on Sat Dec 16 18:43:29 UTC 2023
|
PRIMARY | |||
|
DTXSID301337376
Created by
admin on Sat Dec 16 18:43:29 UTC 2023 , Edited by admin on Sat Dec 16 18:43:29 UTC 2023
|
PRIMARY | |||
|
RD-162
Created by
admin on Sat Dec 16 18:43:29 UTC 2023 , Edited by admin on Sat Dec 16 18:43:29 UTC 2023
|
PRIMARY | |||
|
5ZE6THH5VF
Created by
admin on Sat Dec 16 18:43:29 UTC 2023 , Edited by admin on Sat Dec 16 18:43:29 UTC 2023
|
PRIMARY | |||
|
915087-27-3
Created by
admin on Sat Dec 16 18:43:29 UTC 2023 , Edited by admin on Sat Dec 16 18:43:29 UTC 2023
|
PRIMARY |